Camrelizumab with targeted radiation for limited nasopharyngeal cancer spread
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether combining camrelizumab (an immune medicine) with stereotactic body radiotherapy (high-precision radiation) works better than camrelizumab alone. It’s for people whose nasopharyngeal cancer has spread to a small number of spots in the body and may help control those metastases longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old, and you can take part as either a woman or man
- You finished full/curative radiation to the main tumor and nearby lymph nodes at least 3 months ago, and scans show it’s well controlled
- You have already had at least one type of chemotherapy for advanced disease
- Your scans show only a small amount of spread: no more than 5 total metastatic spots, and no more than 3 in one organ
- Your health is good enough (ECOG score 0 or 1) and your doctors can treat all spots with stereotactic body radiotherapy
- You can safely receive radiation: brain metastasis (if any) must be 3 cm or smaller, and other metastases (not in brain) must be 5 cm or smaller
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests adding a PD-1 “immunotherapy” medicine (a type of cancer-fighting antibody) along with stereotactic body radiotherapy (very focused radiation) to treat nasopharyngeal cancer that has spread to only a few places. It may help shrink remaining visible spots after initial local radiation and see whether this “consolidation” approach improves control of the cancer.
This trial studies whether adding targeted radiotherapy (SBRT) to PD-1 immunotherapy plus capecitabine can improve outcomes for people with newly diagnosed metastatic nasopharyngeal cancer. You may be eligible if your cancer has responded at least to “stable disease” after an initial chemo-immunotherapy course.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This Phase 2 trial studies whether adding camrelizumab (an immune medicine) to stereotactic body radiation (focused, high-precision radiation) helps people with recurrent or metastatic nasopharyngeal cancer. It aims to improve control of the cancer (and may use blood EBV levels to help track response).
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
This Phase 2 trial studies whether adding toripalimab (an immune therapy) to radiation can control nasopharyngeal cancer that has spread only to a few places. It may help by boosting the immune system while the radiation treats the tumor sites.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.